Full screen

Share

NET
Fisiopatología
Sx carcinoide
constituyen un grupo de neoplasias malignas derivadas de células precursoras neuroendocrinas que pueden surgir en cualquier parte del cuerpo.
Tumores neuroendócrinos
Want to create interactive content? It’s easy in Genially!

Over 30 million people create interactive content in Genially.

Check out what others have designed:

Transcript

NET

Fisiopatología

Sx carcinoide

Tumores Neuroendócrinos

PET

Tumores Neuroendócrinos

PET

Sx Carcinoide

Diagnóstico

Sx Carcinoide

Clínica

Sx Carcinoide

constituyen un grupo de neoplasias malignas derivadas de células precursoras neuroendocrinas que pueden surgir en cualquier parte del cuerpo.

  1. Scopel M, De Carlo E, Bergamo F, Murgioni S, Carandina R, Cervino AR, Burei M, Vianello F, Zagonel V, Fassan M, Vettor R. Metástasis óseas de tumores neuroendocrinos: consideraciones clínicas y biológicas. Endocr Connect. 2022 Junio 27;11(7):e210568. doi: 10.1530/EC-21-0568. PMID: 35671272; PMCID: PMC9254287.
  2. Hou J, Long T, Yang N, Chen D, Zeng S, Zheng K, Liao G, Hu S. Biodistribution of 18F-AlF-NOTA-octreotide in Different Organs and Characterization of Uptake in Neuroendocrine Neoplasms. Mol Imaging Biol. 2021 Dec;23(6):827-835. doi: 10.1007/s11307-021-01628-7. Epub 2021 Jul 6. PMID: 34231107.
  3. Refardt, J., Hofland, J., Wild, D. et al. Nuevas direcciones en la obtención de imágenes de neoplasias neuroendocrinas. Curr Oncol Rep 23, 143 (2021). https://doi.org/10.1007/s11912-021-01139-2
  4. Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s. doi: 10.6061/clinics/2018/e490s. PMID: 30133565; PMCID: PMC6096975.
  5. Marina Tsoli, Gregory Kaltsas, Carcinoid Syndrome, Editor(s): Ilpo Huhtaniemi, Luciano Martini, Encyclopedia of Endocrine Diseases (Second Edition), Academic Press, 2019, Pages 13-20, ISBN 9780128122006, https://doi.org/10.1016/B978-0-12-801238-3.65346-1.
  6. Long T, Yang N, Zhou M, Chen D, Li Y, Li J, Tang Y, Liu Z, Li Z, Hu S. Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms. Clin Nucl Med. 2019 Jun;44(6):452-458. doi: 10.1097/RLU.0000000000002578. PMID: 30985413.
  7. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Aug 30;: PMID: 28547177.
  8. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015 Mar-Apr;35(2):500-16. doi: 10.1148/rg.352140164. PMID: 25763733.

Bibliografía

Tumores neuroendócrinos